Breast Cancer Clinical Trial
Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
Summary
This study is designed to evaluate the impact of Zometa on clearance of bone marrow micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density; and quality of life in women undergoing treatment for locally advanced breast cancer.
Eligibility Criteria
Inclusion Criteria:
Newly diagnosed primary invasive ductal or invasive lobular breast adenocarcinoma
Tumor classified as clinically large T2 (2-5 cm), T3, T4 or any T with N1, N2
Prior malignancies: limited to curatively treated basal or squamous carcinoma of the skin or history of previous malignancies, treated and now > 5 years disease free
>= 18 years of age
Normal left ventricular function by echocardiogram or radioventriculogram
Karnofsky Performance >= 70
Exclusion Criteria:
No evidence of distant metastasis present by CT, Bone scan, or physical exam
If the bone scan or CT scans demonstrate indeterminate lesions, the nature of these lesions may be further clarified by additional testing such as PET or MRI
No current treatment with Zometa or other bisphosphonates
No serious functional disorders of the liver or kidneys:
Serum Creatinine <=2
ALT/AST/ALK Phos <= 1.5 x upper limit of institutional normal.
Bili <= 1.5 x upper limit of institutional normal.
Currently not pregnant
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
St. Louis Missouri, 63110, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.